New Delhi, 15 May (IANS). In April this year, the Indian Pharma Market (IPM) has registered a 7.4 percent increase in an annual basis due to the rise in chronic therapy. This information was given in a report on Thursday.
The monthly report by Motilal Oswal Financial Services showed that in April 2024, IPM recorded 9 percent increase and 9.3 percent in March 2025.
This year this year was caused by strong performance in heart, CNS and respiratory medicine.
Especially in April this year, respiratory medicine has seen improvement on an annual basis.
The season saw an increase of 6 percent in acute therapy in April, which was 6 percent in April 2024 and 8 percent in March 2025.
Factors like price, new launch and volume growth were important for the annual increase of IPM in April this year.
Price, new launch and volume growth contributed to 4.3 percent, 2.3 percent and 1.3 percent respectively.
In addition, the report states that the industry has registered an increase of 7.9 percent annually on the basis of Moving Average Total (MAT).
In April 2025, where there was a 9 percent increase on an annual basis regarding chronic therapy. At the same time, 6 percent increase was recorded on acute therapy.
Acute segment stake in the total IPM on April 2025 MAT basis was 61 percent, with an increase of 7.9 percent on an annual basis.
In addition, 11.3 percent in cardiac, 9.4 percent in gastro, antigyoplast (antiquaresner drugs or chemotherapy drugs) and 13.1 percent increase in urology.
The report also stated that domestic companies performed better than multinational companies in April. As of April, Indian pharma companies have a stake of 83 percent in IPM, while the rest of the multinational pharma companies (MNCs) have.
In March this year, the growth rate of Indian companies was 7.4 percent, while the growth rate of MNC was 7.4 percent on an annual basis.
-IANS
SKT/ABM